Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9516
Title: | The antiatherogenic effects of amlodipine: promise of preclinical data. | Austin Authors: | Nayler, W G | Affiliation: | Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia | Issue Date: | 1-Dec-1992 | Publication information: | Journal of Human Hypertension; 6 Suppl 1(): S19-23 | Abstract: | Atherosclerosis is a complex and multifactorial disease, the endpoint of which is the formation of a calcified plaque. Intermediate events include intimal injury, smooth muscle cell proliferation and migration, macrophage infiltration, lipid accumulation and excess formation of ground substance. To determine whether the newly developed, long-acting calcium antagonist, amlodipine, slows the development of atherosclerotic lesions under experimental conditions, young New Zealand white rabbits were fed on a diet of 2% cholesterol plus 1% peanut oil for up to 12 weeks. Half the rabbits received 1 or 5 mg amlodipine/kg body weight/day. Amlodipine caused a significant and dose-dependent reduction in lesion formation in the thoracic aorta. At the same time thoracic aorta Ca2+ and cholesterol content were maintained at near normal levels, despite the raised plasma cholesterol levels. The protective effect of amlodipine persisted throughout a treatment period of 12 weeks, indicating the absence of tachyphylaxis. | Gov't Doc #: | 1284082 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/9516 | Journal: | Journal of human hypertension | URL: | https://pubmed.ncbi.nlm.nih.gov/1284082 | Type: | Journal Article | Subjects: | Amlodipine.pharmacology Animals Aorta.chemistry.pathology Arteriosclerosis.metabolism.prevention & control Calcium.analysis.metabolism Cholesterol.analysis.blood.metabolism Dose-Response Relationship, Drug Male Rabbits Staining and Labeling Time Factors |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.